Immunovant, Inc. (IMVT) company profile
Close on Nov 13, 2026Market cap $7.06BP/E –Yield –
About Immunovant
Biological Products, (No Diagnostic Substances), SIC 2836
Immunovant, Inc. is a clinical-stage immunology company focused on developing targeted treatments for individuals suffering from autoimmune disorders. Its lead candidate is IMVT-1402 (imeroprubart), a fully human monoclonal antibody designed to inhibit the neonatal fragment crystallizable receptor (FcRn) and lower levels of pathogenic immunoglobulin G antibodies. The company develops treatments intended for subcutaneous delivery via an autoinjector across multiple disease areas, including endocrinology, rheumatology, neurology, and dermatology. Its prospective customer and patient base includes individuals affected by conditions such as Graves' disease, difficult-to-treat rheumatoid arthritis, cutaneous lupus erythematosus, and Sjögren's disease.
The company directs its clinical programs toward patient populations across the United States and Europe, having also evaluated IMVT-1402 in clinical trials conducted in New Zealand. The provided excerpt does not disclose the location of Immunovant's corporate headquarters or specific facility counts.
Summary of the business section of Immunovant's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Immunovant, Inc.
- Headquarters
- Durham, NC
- Address
- 1000 Park Forty Plaza 27713
- Phone
- (917) 410-3120
- Website
- immunovant.com
- Employees
- 315, Mar 31, 2026
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- March 31
- Auditor
- Ernst& Young LLP, Iselin, New Jersey
Stock & identifiers
- Ticker
- IMVT
- Exchange
- Nasdaq
- IPO date
- May 10, 2019
- Shares outstanding
- 207M, Aug 3, 2026
- Public float
- $1.25B, Sep 30, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 10-for-3, Feb 14, 2020
- SEC CIK
- 1764013
- CUSIP
- 45258J102
- ISIN
- US45258J1025
- FIGI
- BBG00P5MC0Q8
- Share class FIGI
- BBG00P5MC0R7
- EIN
- 83-2771572
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Eric Venker | Chief Executive Officer, Director | 257,075 |
| Peter Salzmann | Chief Executive Officer, Director | 1,178,191 |
| Tiago Girao | Chief Financial Officer | 234,192 |
| Jay S. Stout | Chief Technology Officer | 198,937 |
| Tuyl Christopher Van | Chief Legal Officer | 175,218 |
| Melanie Gloria | Chief Operating Officer | 217,060 |
| Michael Geffner | Chief Medical Officer | 217,958 |
| Eva Renee Barnett | Chief Financial Officer | 396,774 |
| William L. Macias | Chief Medical Officer | 357,353 |
| Mark S. Levine | Chief Legal Officer | 319,228 |
| Atul Pande | Director | 136,731 |
| Andrew J. Fromkin | Director | 131,400 |
| Robert Graham Susman | Director | 36,394 |
| Douglas J. Hughes | Director | 134,653 |
| Jake Bauer | Director | 38,896 |
| Frank Torti | Director | 1,009,228 |
| Sciences Ltd. Roivant | Director | 113,317,007 |
| George V. Migausky | Director | 157,251 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2026 Eric Venker | $20.16M | $30.28M | $4.09M | $155 | $129 |
| FY2026 Peter Salzmann | $15.33M | $12.21M | $4.09M | $155 | $129 |
| FY2025 | $10.73M | -$9.32M | $4.89M | $107 | $93 |
| FY2024 | $8.55M | $42.52M | $3.87M | $201 | $96 |
| FY2023 | $5.82M | $28.19M | $1.99M | $97 | $89 |
| FY2022 | $5.87M | -$12.30M | $5.63M | $34 | $89 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2026
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Eric Venker Chief Executive Officer | $636.62K | $503.35K | – | $19.01M | $8.17K | $20.16M | – |
| Tiago Girão Chief Financial Officer | $455.49K | $224.40K | $3.63M | $3.29M | $11.32K | $7.62M | – |
| Melanie Gloria Chief Operating Officer | $495.00K | $245.03K | $1.16M | $1.15M | $19.04K | $3.07M | -45% |
| Jay Stout Chief Technology Officer | $495.00K | $245.03K | $1.16M | $1.15M | $17.65K | $3.07M | -23% |
| Christopher Van Tuyl Chief Legal Officer and Corporate Secretary | $495.00K | $245.03K | $771.96K | $766.73K | $17.06K | $2.30M | -61% |
| Peter Salzmann Former Chief Executive Officer | $39.61K | – | $8.29M | $6.27M | $737.64K | $15.33M | +43% |
| Eva Renee Barnett Former Chief Financial Officer | $26.25K | – | $1.35M | $1.46M | $387.43K | $3.23M | -19% |
| Michael Geffner Former Chief Medical Officer | $345.52K | – | $2.56M | $2.15M | $198.58K | $5.25M | +30% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
SPAC offering
- Type
- SPAC (blank check) IPO of units
- Final prospectus filed
- May 10, 2019
- Securities offered
- 10,000,000
- Exchange
- Nasdaq
- First trading day
- Jun 21, 2019
- First-day close
- $9.95
- Lock-up ends (est.)
- Dec 18, 2019
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of March 31, 2026, we had 315 full-time permanent employees, primarily in the U.S.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jun 15, 2020 | Delisting | Notice of delisting from exchange (Form 25) |
| Dec 20, 2019 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 20, 2019 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Dec 20, 2019 | Name change | Name changed from Health Sciences Acquisitions Corp to Immunovant, Inc. |
| Nov 27, 2019 | Merger vote | Definitive merger proxy statement |
| May 10, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| May 9, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?